-
The implementation rules for the management of Chinese medicine formula granules are issued in many places. A large number of Chinese medicines are included in the medical insurance
Time of Update: 2021-12-09
With the advancement of the time for traditional Chinese medicine formula granules to enter the medical insurance, all provinces have begun to act01 A large number of drugs will be included in medical
-
The KRAS G12C inhibitor imported by Zai Lab exceeds RMB 300 million for clinical application
Time of Update: 2021-12-09
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn November 1, the CDE official website showed that the clinical application of Mirati/Zai Lab's highly selective and potent oral KRAS G12C small molecule inhibitor MRTX849 tablets (adagrasib) was officially accepted by the State Food and Drug Administration .
-
The review date of Legendary Bio's BCMA CAR-T cell therapy was postponed by the U.S. FDA for 3 months
Time of Update: 2021-12-09
In a brief statement, Nanjing Legend and Yang Sen stated that the postponement is to "enough time to review information on an updated analytical method following a recent FDA information request .
-
The first domestic extracorporeal membrane oxygenation equipment has been successfully applied in clinical practice
Time of Update: 2021-12-09
The First Affiliated Hospital of Xi’an Jiaotong University stated that the domestic ECMO was successfully applied in clinical practice, breaking the monopoly of foreign products in this field, achieving a breakthrough in the independent research and development of major domestic medical devices , and breaking the "card" for the treatment of critically ill patients with cardiovascular disease.
-
Connaught Bio-targeted MASP-2 innovative antibody CM338 was approved for clinical use
Time of Update: 2021-12-09
ArticleMedicine GuanlanOn November 1, Connoa Biosciences announced that the company's self-developed MASP-2 innovative monoclonal antibody drug CM338 has obtained clinical trial approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration .
-
Changes in the management of many pharmaceutical companies!
Time of Update: 2021-12-09
Tong Yu will join the Janssen China management team as the vice president and head of the Medical Affairs Department from now on .
Tong Yu will work with Zhang Lei, the acting head of Yangsen China Medical Affairs Department, for several weeks.
-
【Big Data Perspective】The innovation pattern of China's biopharmaceuticals
Time of Update: 2021-12-09
Figure 2 Distribution of innovative biological drug treatment fields declared in 2016-2020 (according to generic names)Approval pattern of innovative biopharmaceuticals in ChinaFigure 3 shows the changes in the number of generic names of innovative biopharmaceuticals approved by China and the United States .
-
Boehringer Ingelheim and King's College London join forces to advance new treatment concepts for major depression and schizophrenia
Time of Update: 2021-12-09
Ingelheim, Germany and London, England, November 3, 2021/PRNewswire/ - Boehringer Ingelheim and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London announced a new collaboration on September 27 , The collaboration focused on understanding the brain circuit dysfunction of major depression (MDD) and schizophrenia (SZ), which can lead to cognitive impairment in patients .
-
up to date!
Time of Update: 2021-12-09
The budesonide suspension for inhalation ranks the first in the terminal inhalation products of public medical institutions in China in 2020, with sales of more than 5 billion yuan, and the market share of the original research drug company AstraZeneca is as high as 94.
-
The "three high" drugs are here for purchase!
Time of Update: 2021-12-09
On November 5th, the Henan Provincial Medical Insurance Bureau issued the "Announcement on the Procurement of Drug Alliance of the 13 Provinces (Cities, Districts, and Corps) of Henan, Mongolia, Jiangxi, Jiangxi, Guangdong, Guiyu, Yunnan, Shaanxi, Qingning, and Ningxin Corps (1)", announcing the "Relevant drugs are purchased in quantity .
-
How do post-collection pharmaceutical companies control R&D risks?
Time of Update: 2021-12-09
To this day, although the current two-invoice system and centralized procurement have promoted the urgency of enterprises for drug R&D and innovation, the requirements for drug R&D are also higher and the cost is greater, and the market environment is more demanding, so we need to use more A lot of wisdom to solve the problems faced at that time: how to evaluate the value of new drugs?
-
Menarini receives FDA orphan drug designation for acute myeloid leukemia drug
Time of Update: 2021-12-09
gov number NCT03008187) is the first human phase I/II dose upgrade and cohort expansion trial of SEL24/MEN1703, and it was studied as a single agent for the treatment of patients with relapsed/refractory AML .
-
Kras/PD-1 combined first-line lung cancer debut
Time of Update: 2021-12-09
newsnewsToday Mirati announced some data from its Kras inhibitor adagrasib and Merck’s K drug combination in a 1b clinical trial called KRYSTAL-1 .
Kras inhibitors have a larger therapeutic window for patients with Kras variant tumors, so the combination with K drugs may be better tolerated .
-
Competition in the PI3K inhibitor market has increased
Time of Update: 2021-12-09
A few days ago, Incyte announced that the FDA has accepted a new generation of phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor parsaclisib for the treatment of relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma New Drug Application (NDA) for Type 3 Non-Hodgkin’s Lymphoma (MCL) .
-
A new generation of anti-flu drugs!
Time of Update: 2021-12-09
According to information on Zhengxiang's official website, ZX-7101A is a new generation of oral anti-influenza drug independently developed by the company .
Retrieved Nov 1, 2021, from http:// The clinical trial application of Zhengxiang Medicine's new anti-influenza drug ZX-7101A was officially approved by NMPA.
-
For social anxiety!
Time of Update: 2021-12-09
Public information shows that PH94B is a potential "first-in-class", fast-acting neurosteroid drug candidate under development by VistaGen, and it has entered a phase 3 clinical study for the treatment of social anxiety disorder (SAD) worldwide .
-
The State Food and Drug Administration approves the listing of Yinqiao Qingre Tablets, an innovative Chinese medicine drug
Time of Update: 2021-12-08
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets . Jiangsu Kangyuan Pharma
-
The biopharmaceutical industry accelerates its development towards high quality, and the performance of pharmaceutical machinery companies may usher in new growth
Time of Update: 2021-12-08
For example, Jiangsu Province recently issued "Several Policies and Measures on Promoting the High-Quality Development of the Province’s Biomedicine Industry", which clearly stated that by 2024, the basic capabilities of Jiangsu’s biomedical industry and the modernization level of the industrial chain must continue to be improved.
-
The medical insurance adjustment will be completed before the end of the year. The industry recommends grasping the investment opportunities of innovative drugs and CXO
Time of Update: 2021-12-08
After the price drop, third-party data pointed out that the drugs included in the medical insurance catalog after medical insurance negotiations from 2017 to 2019 have achieved 128%, 337%, and 39% growth in sales in 2020 relative to the year of inclusion .
-
Multinational pharmaceutical companies release third-quarter financial reports: Pfizer and Merck have outstanding performance
Time of Update: 2021-12-08
534 billion; sales of GARDASIL/GARDASIL 9 (HPV vaccine) increased by 68% year-on-year to US$1.
Among them, the total revenue of Roche Diagnostics in the first three quarters increased by 38% year-on-year to 13.
